98%
921
2 minutes
20
Objective: To gather comprehensive insights regarding current neuropsychological assessment practices in PRECISION-ALS, a pan-European research and industry consortium, to propose areas which can be harmonized and facilitate more robust cross-country comparisons.
Methods: Representatives from PRECISION-ALS sites were surveyed with a semi-structured interview, gathering information on how people with ALS are assessed for cognitive/behavioral change, including how they are initially screened, classified as impaired/unimpaired, and followed up longitudinally. Assessment practices across PRECISION-ALS sites were summarized using descriptive analysis.
Results: Ten of the eleven PRECISION-ALS sites perform cognitive and/or behavioral screening at least once during the course of the disease, using the Edinburgh Cognitive and Behavioral ALS Screen, either for clinical or research purposes. All centers categorize impairment, but differ how it is defined, with some using local norms, and others using other countries' norms. Most sites account for age and education, but differ in how these factors are considered. Longitudinal protocols vary in terms of the number of assessments, time intervals, and use of alternative versions. Behavioral screening is more consistently implemented, with the ECAS caregiver interview as the standard tool, however there is a lack of clarity in how this data is applied. Many sites supplement cognitive and behavioral screening with additional measures of mood and/or neuropsychiatric symptoms.
Conclusions: These findings illustrate areas of commonality and divergence in neuropsychological screening practices. Site-specific variations are likely to confound research involving cross-country data-sharing. PRECISION-ALS, in generating prospective population-based datasets, will provide agreed harmonized protocols for neuropsychological assessment across participating sites.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/21678421.2025.2527877 | DOI Listing |
J Neural Transm (Vienna)
September 2025
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 40139, Italy.
Multisystem proteinopathy 1 (MSP1) is a rare autosomal dominant disorder caused by mutations in the valosin-containing protein (VCP) gene typically presenting with inclusion body myopathy (IBM), Paget's disease of bone (PDB), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). Parkinsonism is a rare feature of MSP1, occurring in 3-4% of cases, with limited post-mortem evidence suggesting neuronal synucleinopathy. We report a case of VCP-related parkinsonism providing the first in vivo demonstration of phosphorylated alpha-synuclein deposition in skin biopsy, a highly sensitive and specific in vivo biomarker of synucleinopathy.
View Article and Find Full Text PDFJ Autism Dev Disord
September 2025
The Melbourne Clinic Neuropsychology Service, 130 Church St, Richmond, Melbourne, VIC, 3121, Australia.
Investigate the utility of a neuropsychological strengths-based approach to the assessment of Autism in adults; to determine the acceptability of the approach and feedback provided to clients; and gather information about improving the assessment process for future clients. The approach was grounded in a neurodiversity-positive framework, providing diagnosis-affirming care. Participants were inpatient clients of the neuropsychology service of a private adult, mental health treatment service.
View Article and Find Full Text PDFBrain Behav Immun
September 2025
Department of Public Health Science, Graduate School and Transdisciplinary Major in Learning Health Systems, Graduate School, Korea University, Seoul, South Korea. Electronic address:
Background: Immune dysregulation and metabolic disturbances contribute to cognitive decline in aging populations. The neutrophil-to-HDL cholesterol ratio (NHR), an emerging immunometabolic biomarker, reflects systemic inflammation and vascular dysfunction. However, its role in predicting cognitive impairment in older adults remains unclear.
View Article and Find Full Text PDFNeurology
October 2025
Department of Radiology, Mayo Clinic, Rochester, MN.
Background And Objectives: The relationship between insomnia and cognitive decline is poorly understood. We investigated associations between chronic insomnia, longitudinal cognitive outcomes, and brain health in older adults.
Methods: From the population-based Mayo Clinic Study of Aging, we identified cognitively unimpaired older adults with or without a diagnosis of chronic insomnia who underwent annual neuropsychological assessments (z-scored global cognitive scores and cognitive status) and had quantified serial imaging outcomes (amyloid-PET burden [centiloid] and white matter hyperintensities from MRI [WMH, % of intracranial volume]).
Gerontologist
September 2025
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612United States.
Background And Objectives: Cognition may be influenced by health-related factors such as blood pressure (BP). However, variations in BP may differentially affect cognition across race. This study investigates BP and cognitive decline in older Black and White adults.
View Article and Find Full Text PDF